Aspen Pharmacare

The next three to five years will require the continent to ensure there is sustainable business beyond Covid-19.

Your Africa updates: What happened on the continent this past week

South Africa is still awaiting millions of Covid-19 vaccines from Johnson & Johnson even though the country contributed to its research through the Ensemble and Sisonke studies

For all the excitement generated by the news of an mRNA vaccine hub being established in South Africa, the country is still going to need help making Covid-19 jabs

South Africa has doubled the interval for the second dose of the Pfizer vaccine. We take a look at what other countries have done and the evidence for the move

Hospitals are under strain, nurses are burning out and infections are on the rise, but there are limited Covid-19 vaccine doses available

It is no good waiting for a vaccine or ivermectin or other miracle cures, we just need to do what we can do now

We spoke to experts, looked at the data and relistened to the health department’s briefings to break down the revised roll-out plan

Adcock Ingram, SA’s largest supplier of hospital products, may gain a further 12% from a 30-month high after it got takeover offers.

A tale of two companies — one saw generics as the future, the other is playing catch-up.

Africa’s biggest generic drug-maker, Aspen Pharmacare, said on Monday full-year headline earnings per share likely rose by 25%.

Aspen Pharmacare, Africa’s biggest generic drug-maker, posted a 27% rise in first-half profit from continuing operations.

The Beijing Olympics has had an unexpected side effect, which is being felt locally in the form of serious shortages of generic medicines.

The awarding of a new tender for antiretroviral drugs by the Health Department will mean important savings for the state’s treatment programme.